Antirheumatic drug abatacept delayed the onset of rheumatoid arthritis for up to four years among patients at high risk of ...

A promising new study suggests rheumatoid arthritis may not be as inevitable as once thought for people at high risk.

BARCELONA, Spain — Treatment with abatacept delays the onset of rheumatoid arthritis (RA) in patients at high risk of developing the disease, according to data presented at the European Alliance of ...

"Real-world" data from the Swedish Rheumatology Quality register show that patients with rheumatoid arthritis (RA) for whom abatacept (Orencia, Bristol-Myers Squibb) is the first biologic ...

Please provide your email address to receive an email when new articles are posted on . Abatacept treatment after ustekinumab withdrawal did not prevent psoriasis relapse, according to a randomized ...

The risk or severity of infection can be increased when Adalimumab is combined with Abatacept. The risk or severity of adverse effects can be increased when Abatacept is combined with Bacillus ...

Among individuals at high risk for the development of rheumatoid arthritis (RA), treatment with abatacept (Orencia) helped reverse inflammation, with the implication that such treatment may prevent or ...

Add Yahoo as a preferred source to see more of our stories on Google. Abatacept eases symptoms and prevents joint damage in rheumatoid arthritis patients by dampening the immune system, researchers ...

Patients with rheumatoid arthritis (RA) who also had chronic obstructive pulmonary disease (COPD) had no increased risk of serious respiratory complications when treated with abatacept (Orencia), a ...

Please provide your email address to receive an email when new articles are posted on . A recent study on the benefits of abatacept for patients with moderate-to-severe Crohn’s disease or ulcerative ...

A new study reports that B7-1 is not expressed on the podocytes of patients or mice with diabetic nephropathy. In contrast to the findings of some previous studies, these data suggest that targeting ...

Upadacitinib is an oral selective Janus kinase inhibitor to treat rheumatoid arthritis. The efficacy and safety of upadacitinib as compared with abatacept, a T-cell costimulation modulator, in ...